Bionter is a technology company.
Bionter has raised $3.0M across 1 funding round.
Bionter has raised $3.0M in total across 1 funding round.
Bionter AG is a Swiss medtech startup founded in 2020 that develops advanced particulate matter testing solutions for the pharmaceutical and biotechnology industries[1][2][3]. Its flagship product, EVE, is a fully automated particle counter using light obscuration technology for non-destructive subvisible particle analysis in parenteral drugs and ophthalmic solutions, reducing sample volume, costs, and human error while ensuring USP/EP/JP regulatory compliance[1][3][4]. Bionter serves biopharma manufacturers by improving drug product quality, patient safety, efficiency, and sustainability; it secured $3 million in seed funding in 2022 from Dynamk Capital to expand its team and launch EVE commercially in Europe and the US, achieving early prototype success with global pharma clients[1][3][7].
Bionter was established in 2020 in Riehen, Switzerland, by a team with deep expertise in particle analytics and commercialization of testing products[1][2]. The idea emerged from addressing inefficiencies in traditional subvisible particle testing, where high sample volumes waste material and manual processes risk errors in biopharma quality control[3][4]. Key early milestones include prototype testing with global pharma companies, seed funding led by US investor Dynamk Capital, and the 2022 launch of EVE after completing patented technology development; partnerships like with Midwest Bio expanded its North American reach[1][3]. Participation in accelerators such as Venture Leaders Biotech 2022 further boosted visibility among investors and industry leaders[4].
Bionter rides the wave of biopharma quality control demands amid rising biologics production, where subvisible particles pose risks to patient safety and regulatory approval[1][3]. Its timing aligns with post-pandemic emphasis on efficient, sustainable manufacturing—reducing sample needs supports resource-scarce biotech scaling amid supply chain pressures[2][3]. Market forces like stringent USP/EP/JP rules and cost pressures favor disruptive tools like EVE, influencing the ecosystem by enabling faster drug development, lowering barriers for smaller biotechs, and partnering with CROs like Solvias for broader adoption[1][3].
Bionter's momentum from seed funding and EVE launch positions it for rapid growth in the $multi-billion particle testing market, with plans to expand its pipeline of automated solutions[3][7]. Trends like AI-driven analytics and single-use tech in biopharma will amplify its edge, potentially attracting Series A investment and global partnerships. As biotechs prioritize quality at scale, Bionter could redefine standards, evolving from niche innovator to essential player in drug safety—building on its mission to accelerate safer medicines from day one[2][3].
Bionter has raised $3.0M in total across 1 funding round.
Bionter's investors include Dynamk Capital.
Bionter has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $3.0M Seed | Dynamk Capital |